Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 127 clinical trials
Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)

This is a prospective, observational, multi-center and post-authorization safety study that includes patients with a diagnosis of Neovascular Glaucoma. The investigator will have made the decision to use Eylea for treatment. The objective of this study is to assess safety and effectiveness of Eylea using in real clinical practice. Patients …

  • 0 views
  • 04 Sep, 2021
  • 1 location
Single In-Clinic Encounter With the Notal Vision Home OCT

this is a single In-Clinic Encounter With the Notal Vision Home OCT study. The study population will include up to 50 Age-related Macular Degeneration patients diagnosed with wet NV-AMD in at least one eye at the time of enrollment. All enrolled subjects should have at least one eye with active …

  • 0 views
  • 10 Sep, 2021
  • 1 location
Dark Adaptation in Participants With Age-Related Macular Degeneration

Background Macular degeneration can cause permanent loss of central vision. This vision is important for seeing details. Age-related macular degeneration (AMD) is the leading cause of vision loss in people over 55 in the United States. Researchers want to follow people with AMD to study the early to middle stages …

blindness
eye exam
vision test
age-related macular degeneration
ophthalmic solution
  • 0 views
  • 02 Sep, 2021
  • 1 location
Retrospective Analysis of Naive Patients With Age-related Macular Degeneration Neovascular Type and Treated With Ranibizumab (Lucentis ) in "Treat-and-extend" at the CHU Brugmann.

Age-related macular degeneration (AMD) is a leading cause of blindness in people over 50 years old. Neovascular AMD, the most severe form and the most severe is characterized by the appearance, spread and growth of subretinal neovessels. One of the major molecular mediators is the endothelial growth factor vascular (VEGF). …

blindness
lucentis
ranibizumab
vegf
vascular endothelial growth factor
  • 0 views
  • 13 Aug, 2021
  • 1 location
A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab in Patients With nAMD

This study is a prospective, uncontrolled, central registration system, multicenter, domestic observational study (special drug-use surveillance) to evaluate the safety of 52-week clinical treatment with Beovu kit for intravitreal injection in nAMD patients.

  • 0 views
  • 26 Sep, 2021
  • 66 locations
"Mechanisms and Biomarkers of Response and Resistance to Current Targeted Therapies in Gastric Cancer" (THERRES)

Our aim was to assess the tumor vascular perfusion pattern in gastric cancer (GC). We used dynamic contrast harmonic imaging endoscopic ultrasound (CHI-EUS) and then we compared the result with the immunohistochemical expression of CD105 and clinico-pathological parameters.

endoscopic ultrasound
  • 0 views
  • 26 Sep, 2021
Epitranscriptomic Blood Biomarkers for Coronary Artery Disease - A Prospective Cohort Study (IHD-EPITRAN)

Despite advancements in medical care, ischemic heart disease (IHD) remains the leading global cause of death. IHD develops through lipid accumulation into the coronary arteries with subsequent formation of larger atherogenic plaques. During myocardial infarction (MI), a plaque ruptures and subsequent occlusion leads to a death of the heart muscle. …

  • 0 views
  • 26 Jan, 2021
  • 1 location